Incyte Corporation (INCY)
| Market Cap | 24.54B +36.4% |
| Revenue (ttm) | 6.01B +24.9% |
| Net Income | 403.41M -66.1% |
| EPS | 1.94 -67.1% |
| Shares Out | 203.83M |
| PE Ratio | 61.93 |
| Forward PE | 14.68 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,840,253 |
| Open | 120.10 |
| Previous Close | 116.80 |
| Day's Range | 119.55 - 122.87 |
| 52-Week Range | 89.25 - 132.60 |
| Beta | 0.74 |
| Analysts | Buy |
| Price Target | 130.63 (+8.51%) |
| Earnings Date | Oct 29, 2026 |
About INCY
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for... [Read more]
Financial Performance
In 2025, Incyte's revenue was $5.14 billion, an increase of 21.22% compared to the previous year's $4.24 billion. Earnings were $1.29 billion, an increase of 3844.96%.
Financial StatementsAnalyst Summary
According to 28 analysts, the average rating for INCY stock is "Buy." The 12-month stock price target is $130.63, which is an increase of 8.51% from the latest price.
News
Incyte price target lowered to $116 from $119 at Morgan Stanley
Morgan Stanley analyst Chris Yu lowered the firm’s price target on Incyte (INCY) to $116 from $119 and keeps an Equal Weight rating on the shares. Incyte posted a Q3…
Incyte price target raised to $127 from $125 at Evercore ISI
Evercore ISI analyst Gavin Clark-Gartner raised the firm’s price target on Incyte (INCY) to $127 from $125 and keeps an In Line rating on the shares.
Incyte price target lowered to $127 from $128 at Wells Fargo
Wells Fargo lowered the firm’s price target on Incyte (INCY) to $127 from $128 and keeps an Equal Weight rating on the shares. The firm thought the Q3 update was…
Incyte price target raised to $143 from $139 at Barclays
Barclays analyst Etzer Darout raised the firm’s price target on Incyte (INCY) to $143 from $139 and keeps an Overweight rating on the shares.
Oppenheimer upgrades Incyte on growth outside of Jakafi
Oppenheimer last night upgraded Incyte (INCY) to Outperform from Perform with a price target of $144, up from $120. The company is “increasingly demonstrating a credible path to growth” beyond…
Incyte upgraded to Outperform from Perform at Oppenheimer
Oppenheimer analyst Jay Olson upgraded Incyte (INCY) to Outperform from Perform with a price target of $144, up from $120.
Incyte Earnings Call Transcript: Q3 2026
Q3 revenue and net sales rose 14% YoY, and FY2026 net sales guidance increased. OPZELURA and hematology/oncology growth brands drove results as late-stage pipeline programs advanced.
Incyte Earnings release: Q3 2026
Incyte released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Incyte Slides: Q3 2026
Incyte has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
Incyte Quarterly report: Q3 2026
Incyte has published its Q3 2026 quarterly earnings report on October 29, 2026.
Incyte reports Q3 EPS ($3.60), consensus ($4.25)
Reports Q3 revenue $1.56B, consensus $1.46B. “Our third quarter was marked by strong commercial performance, meaningful pipeline progress and important regulatory achievements,” said Bill Meury, Chief...
Incyte raises FY26 revenue view to $5.21B-$5.3B from $5.13B-$5.26B
Consensus $5.92B
Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates.
Incyte Transcript: Investor update
'890 plus FOLFOX-bev showed a 71% response rate and 81% six-month PFS in first-line MSS colorectal cancer. '734 showed encouraging activity in pancreatic and later-line colorectal cancer, supporting ongoing and planned pivotal trials.
Incyte Press release: Investor update
Incyte issued a press release on October 26, 2026, disclosing material business information to investors.
Incyte Slides: Investor update
Incyte has posted slides in relation to its latest quarterly earnings report, which was published on October 26, 2026.
Incyte highlights data across gastrointestinal cancer portfolio at ESMO 2026
Incyte (INCY) announced new results from its advancing oncology portfolio, including updated results for its KRAS G12D inhibitor in pancreatic ductal adenocarcinoma and advanced or metastatic colorect...
Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ESMO26--Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026.
Incyte, Genmab announce clinical trial collaboration to evaluate INCB161734
Incyte (INCY) and Genmab A/S (GMAB) announced a clinical trial collaboration to evaluate INCB161734, Incyte’s investigational, potent and selective KRAS G12D inhibitor, in combination with petosemtama...
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
COPENHAGEN, Denmark & WILMINGTON, Del.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab's investiga...
Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
WILMINGTON, Del. & COPENHAGEN, Denmark--(BUSINESS WIRE)---- $INCY--Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer.
Incyte price target raised to $140 from $138 at TD Cowen
TD Cowen raised the firm’s price target on Incyte (INCY) to $140 from $138 and keeps a Buy rating on the shares. The firm decreased their 2026 estimatse to account…
Incyte to present new data on oncology portfolio at ESMO 2026
Incyte (INCY) announced that it will present new data from its oncology portfolio during the European Society of Medical Oncology, ESMO, Congress 2026, being held October 23 – 27, 2026,…
Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ESMO2026--Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026.
Incyte price target raised to $115 from $105 at Truist
Truist analyst Srikripa Devarakonda raised the firm’s price target on Incyte (INCY) to $115 from $105 and keeps a Hold rating on the shares. The firm has updated its model…